Treatment of Nrf2 activator DMF (HG/DMF) partly restored hyperglycemia-induced IL6 secretion, while it completely restored the secretion of IL1β and MCP1 compared to the HG/VEH group. This evidence concerns the gene CCL2 and Hyperglycemia.